Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alanyl-glutamine Supplementation for C. Difficile Infection
NCT02053350Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2015
- Primary completion
- Apr 2017
- Countries
- 1
- Sponsor
- University of Virginia
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Drugs
- alanyl glutamine
- Conditions
- Clostridioides difficile infection (CDI)
01
Overview
Phase 2, randomised, double-blind trial of alanyl glutamine in Clostridioides difficile infection (CDI), sponsored by University of Virginia. Primary endpoints: Number of Participants With Recurrent C. Difficile Infection at 40 days and Mortality at 6 months. Started Apr 2015; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults 18+ (or 50+ per detailed description) with first-time uncomplicated C. difficile infection, hospitalized, receiving standard antibiotics (metronidazole or vancomycin). Excludes severe disease (WBC > 20k, ICU, shock), chronic liver/kidney disease, and other causes of diarrhea.
04
Endpoints
Primary
Number of Participants With Recurrent C. Difficile Infection
Mortality
Beyond the preview
Go deeper on NCT02053350.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053350.